Gavreto (pralsetinib): Increased risk for tuberculosis and measures to minimise this risk

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Gavreto
Active substance
pralsetinib
Therapeutic area (MeSH)
Carcinoma, Non-Small-Cell Lung
Procedure number
EMEA/H/C/005413
Regulatory outcome
Variation
DHPC type
  • Adverse event
  • Post-authorisation measure
Human ATC code
L01XE
Dissemination date
16/06/2023

How useful was this page?

Add your rating